Navigation Links
Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
Date:11/5/2010

e speed at which accessory proteins disassociate from the neurotoxin molecule at physiological pH suggests that the necessity of these proteins in medicinal formulations of botulinum toxin type A is questionable in influencing the therapeutic effects," said Eric J. Pappert, M.D., Vice President of Medical Affairs, Merz Pharmaceuticals, LLC. "Additionally, results from the stability studies evaluating XEOMIN under various conditions suggest that accessory proteins are not required for the long-term maintenance of potency of this medicinal formulation of botulinum toxin type A."

Clinical StudiesThe results of studies exploring the safety and efficacy of XEOMIN in the treatment of adults with cervical dystonia, blepharospasm and post-stroke spasticity of the upper limb will also be presented:

  • Poster 49: Efficacy and safety of NT 201 (Xeomin®; Botulinum neurotoxin free from complexing proteins) in cervical dystonia (Grafe S., et al.)
  • Poster 50: Efficacy and safety of NT 201 (Xeomin®; Botulinum neurotoxin type A free from complexing proteins) for the treatment of blepharospasm: Results of a double-blind, placebo-controlled, randomized, multi-center trial (Jankovic J., et al.)
  • Poster 57: Overall clinical efficacy and overall tolerability of NT 201 (Botulinum neurotoxin free from complexing proteins) (Benecke R., et al.)

  • About XEOMINIn nature, Clostridium botulinum produces the toxin in association with accessory proteins, resulting in a 900 kDa complex. Manufacturers utilize this naturally occurring protein complex to produce therapeutic botulinum toxin products. Merz has introduced XEOMIN (incobotulinumtoxinA), manufactured using a proprietary process that isolates the therapeutic component and eliminates accessory proteins, yielding a 150 kDa neurotoxin molecule.

    More than 84,000 patient shave been treated with XEOMIN worldwide since 2005. The U.S. is the 20th country to approve XEOMIN for the trea
    '/>"/>

    SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
    2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
    3. Romark Announces Data Presented at AASLD Meeting 2010
    4. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
    5. ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
    6. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
    7. New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
    8. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
    9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    10. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
    11. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014  Paper Pak Industries, ... developed APLS ® Body Guard Bio, a ... spread of bacteria and virus while protecting service ... Guard Bio features a rugged, external nylon shell, ... create a leak-proof inner chamber that contains contaminated ...
    (Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
    (Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
    Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2
    ... Registration Trials, HAYWARD, Calif., Sept. 6 Kosan ... has successfully,reached a binding agreement with the U.S. Food ... clinical trial, a pivotal Phase 3 trial,of its Hsp90 ... Through the FDA,s Special Protocol Assessment (SPA),process, Kosan and ...
    ... Prevalence and Continuous,Abstinence by Dose, Schedule and Antibody Response; Nabi to ... ... Today, BOCA RATON, Fla., Sept. 5 Nabi,Biopharmaceuticals (Nasdaq: ... (Nicotine Conjugate Vaccine), the company,s,innovative and proprietary investigational vaccine being developed ...
    Cached Medicine Technology:Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 2Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 3Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 4Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 5Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 6Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months 7
    (Date:10/25/2014)... Recently, the famous review website, Top10BestSEOHosting.com, has ... . According to the site, GoDaddy, Bluehost and ... the world. “Nowadays, Joomla hosting is a very ... hosting. The account owner is allowed to use ... under a specific name, brand or company,” the ...
    (Date:10/25/2014)... York (PRWEB) October 25, 2014 The ... ) will be addressed in December, when the U.S. ... hearing session. According to a Hearing Session Order issued ... the matter will be heard on December 4, 2014, ... at 9:30 a.m. (In Re: Xarelto Products Liability Litigation, ...
    (Date:10/25/2014)... TASC (Total Administrative Services Corporation), ... account management services, announces the release of four ... taxes, reduce administrative workload, and lessen liability. ... the efficient handling of complex, time-sensitive, and labor-consuming ... meets their goals and objectives. The four Suites ...
    (Date:10/25/2014)... October 25, 2014 The federal ... http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific Corp. ... District Court, Southern District of West Virginia has ... Punitive Damages in a group of cases filed ... issued on October 21st, U.S. District Judge Joseph ...
    (Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
    Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: GoDaddy, Bluehost And Hostgator Are Among The Most Excellent Suppliers In The World 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
    ... Inviting, Child-Friendly Online Information Source for ... ... http://www.searchhope.org , LOS ANGELES, March ... created an innovative, inviting,child-friendly web-based portal that allows sick children and ...
    ... damage that can occur in babies with congenital heart disease is ... defect results in too much blood in the lungs, more blood ... blood vessel growth is abruptly halted. , You get this burst ... we think the system gets shut down and the lungs dont ...
    ... NC Researchers at Duke University Medical Center say ... more harm to cardiovascular health in women than in ... Brain, Behavior and Immunity, found that poor sleep is ... biomarkers associated with elevated risk of heart disease and ...
    ... The Children,s,Hospital of Philadelphia is pleased to name ... Nursing Officer. The appointment follows an,extensive national search., ... coming to Children,s Hospital, Esposito-Herr served as the ... of Maryland Medical,Center, where she also held a ...
    ... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... scheduled to,present from 8:30 a.m. to 8:55 a.m. ET, ... Global Healthcare Conference in Miami,Florida., The event will ... web cast,which may be accessed by visiting http://investors.gentiva.com/events.cfm ...
    ... stunted growth , , MONDAY, March 10 (HealthDay News) -- ... patients at risk for bone damage and stunted growth, ... concerns a signal transduction inhibitor (STI) medication known as ... by short-circuiting tumor growth on the molecular level. The ...
    Cached Medicine News:Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 2Health News:Siegel+Gale Designs New 'HOPE Portal' for Childrens Hospital Los Angeles 3Health News:Lung damage in babies with congenital heart disease under study 2Health News:Lung damage in babies with congenital heart disease under study 3Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:The Children's Hospital of Philadelphia Appoints New Chief Nursing Officer 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 3Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 2Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: